
Labs in Court: Two EKRA-Related Cases and Some Usual Suspects
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance
Recent DOJ settlements continue to focus on issues involving medical necessity and marketer compensation
Lab leaders should be wary of telemedicine arrangements, certain marketing firms, and unnecessary PGx and CGx testing
COVID-19-related schemes dominated recent enforcement efforts, which include a national healthcare fraud enforcement action
Genetic testing related fraud was a theme in recent enforcement actions involving medical laboratories and lab testing